12.         Stock-based Compensation

Shares available for grant

The Company's Amended and Restated 2014 Equity Incentive Plan (the "2014 Plan") expired on  January 31, 2024. Following such expiration and prior to the 2024 Annual Meeting of Stockholders (the "Annual Meeting"), no grants were made under the 2014 Plan. On June 6, 2024, the Company held its Annual Meeting and amended and restated the 2014 Plan (the "Restated 2014 Plan") to extend the term of the 2014 Plan until April 15, 2034, and to increase the total number of shares of common stock authorized for issuance by 1,000 shares relative to the amount available for issuance at the time the 2014 Plan expired. As of March 31, 2025, the total number of shares authorized for grant under the Restated 2014 Plan was 4,724, of which 695 were available for future grants.

Restricted Stock Units

The Company issues time-based restricted stock units (“RSUs”) and performance-based restricted stock units ("PSUs") to employees and non-employees. Each RSU and PSU represents the right to receive one share of the Company’s common stock upon vesting and subsequent settlement. PSUs vest upon achievement of performance targets based on the Company's annual operating plan. The fair values of RSUs and PSUs are determined based on the closing price of the Company’s common stock on the date of grant.

RSU activity for the three months ended March 31, 2025 is summarized below:

The total grant-date fair value of RSUs that vested during the three months ended March 31, 2025 was $119. As of March 31, 2025, $499 of total unrecognized compensation expense related to unvested RSUs was expected to be recognized over a weighted average period of 1.25 years.

There was no PSU activity for the three months ended March 31, 2025.

Stock Options

Stock options activity for the three months ended  March 31, 2025, is summarized below:

No stock options were exercised during the three months ended March 31, 2025 and 2024.

As no stock options were granted during the three months ended March 31, 2025 and 2024, there was no related weighted-average grant-date fair value. The total grant-date fair value of stock options vested during the three months ended March 31, 2025 and 2024 was $0.

As of March 31, 2025, total unrecognized compensation cost related to unvested stock options was $0.

Compensation Expense

Stock-based compensation expense is included in the condensed consolidated statements of operations and comprehensive loss in general and administrative, research and development, or sales and marketing expenses, depending on the nature of the services provided. Stock-based compensation expense related to RSUs and PSUs was recorded as follows:

401(k) Plan Share Match

During the three months ended March 31, 2025 and 2024, the Company issued 556 and 163 shares of common stock with a fair value of $236 and $237, respectively, to eligible employees’ deferral accounts for the Ekso Bionics 401(k) plan (the "401(k) Plan") matching contribution representing 50% of each eligible employee’s elected deferral (up to the statutory limit) for the years ended December 31, 2024 and 2023.

The (income) expense, net for the 401(k) Plan share matching was $(25) and $29 for the three months ended March 31, 2025 and 2024, respectively.